

Appendix VI
EXTRAORDINARY INFORMATION DISCLOSURE
(Issued with the Decision No. 21/QĐ-SGDVN on December 21, 2021 of the CEO of Vietnam Exchange on the Information Disclosure Regulation of Vietnam Exchange)

**AGIMEXPHARM PHARMACEUTICAL
JOINT STOCK COMPANY**

THE SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

No.: 07/CBTT-AGP

An Giang, March 25, 2025

EXTRAORDINARY INFORMATION DISCLOSURE

To: Hanoi Stock Exchange

1. Name of organization: AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

- Stock code: AGP
- Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province
- Tel: 02963.856964
- E-mail: agp@agimexpharm.com

2. Contents of disclosure:

- Resolution of the Board of Directors No. 02/NQ-AGP.HDQT dated March 25, 2025, on the Implementation of the plan for share issuance to pay 2024 dividends;
- Resolution of the Board of Directors No. 03/NQ-AGP.HDQT dated March 25, 2025, on the Approval of the implementation procedures for securities offering and issuance.

3. This information was published on the company's website on March 25, 2025, as in the link <https://agimexpharm.com/shareholder/>

We hereby certify that the information provided is true and correct and we bear the full responsibility to the law.

Attached documents:

- Resolution of the BODs No. 02/NQ-AGP.HDQT;
- Resolution of the BODs No. 03/NQ-AGP.HDQT.

Legal representative
General Director


Phan Nguyen Van Kha

RESOLUTION

On approval of the implementation procedures for securities offering and issuance

- Pursuant to Enterprises Law No. 59/2020/QH14 dated June 17, 2020;
- Pursuant to Securities Law No. 54/2019/QH14 dated November 26, 2019;
- Pursuant to Decree No. 155/2020/ND-CP dated December 31, 2020, of the Government detailing and guiding the implementation of certain provisions of the Securities Law;
- Pursuant to Circular No. 118/2020/TT-BTC dated December 31, 2020, of the Ministry of Finance guiding certain contents on securities offering, issuance, public tender offers, share buybacks, public company registration, and public company delisting;
- Pursuant to Resolution No. 01/NQ-AGP.DHDCD dated March 08, 2025, of the 2025 Annual General Meeting of Shareholders;
- Pursuant to Minutes No. 01/BB-AGP.DHDCD dated March 08, 2025, of the 2025 Annual General Meeting of Shareholders;
- Pursuant to Proposal No. 02/TT-AGP.DHDCD dated February 14, 2025, on Profit distribution and Dividend payment;
- Pursuant to Proposal No. 04/TT-AGP.DHDCD dated February 14, 2025, on Approval of the plan for issuing shares to pay dividends for the year 2024;
- Pursuant to Proposal No. 05/TT-AGP.DHDCD dated February 14, 2025, on Approval of the plan for issuing shares under the Employee Stock Ownership Plan (ESOP);
- Pursuant to Minutes No. *02*/BB-AGP.HDQT dated *March 25, 2025* of the Board of Directors;
- Pursuant to Charter of Agimexpharm Pharmaceutical Joint Stock Company ("Company").

RESOLVED:

Article 1: Approval of the specific implementation plan:

Content	Number of shares
A. Number of shares before issuance	23,143,941 shares
Total issued shares	23,143,941 shares
Total outstanding shares	23,143,941 shares
B. Number of shares expected to be issued	3,471,591 shares
Shares to be issued for dividend payment (10%)	2,314,394 shares
Shares to be issued under the Employee Stock Ownership Plan (ESOP) (5%)	1,157,197 shares
C. Number of shares after issuance	26,615,532 shares

Article 2: Approving the implementation procedures for securities offering and issuance to ensure that the issuance of shares for dividend payment and the issuance of shares under the Employee Stock Ownership Plan ("ESOP") comply with the plan approved by the 2025 Annual General Meeting of Shareholders on March 8, 2025 – as detailed in the appendix attached to this Resolution.




Article 3: Authorizing the Chairman of the Board of Directors to sign relevant documents on behalf of the Board of Directors and to direct the implementation of subsequent steps in compliance with applicable regulations.

Article 4: Members of the Board of Directors and the Executive Board of Agimexpharm Pharmaceutical Joint Stock Company are responsible for implementing this Resolution. This Resolution takes effect from the date of signing.

Recipients:

- As stated in Article 4;
- Archived: VT, Secretary of the BODs.

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRWOMAN**



PHẠM THỊ BÍCH THUY

160
IG T
CP
C PH
EXPH
YEN

APPENDIX

**TENTATIVE PROCEDURE FOR THE ISSUANCE OF SHARES FOR DIVIDEND PAYMENT
AND EMPLOYEE STOCK OWNERSHIP PLAN (ESOP) IN COMPLIANCE WITH THE PLAN
APPROVED BY THE 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS ON MARCH 8, 2025**

(Issued together with the Board of Directors' Resolution No. 03/NQ-AGP.HDQT dated 2025)

NO.	CONTENT	TIMELINE (Business days)	NOTES
1	SSC announces receipt of complete issuance report documents for dividend payment and ESOP share issuance.	T	
2	Disclosure of the Announcement on share issuance for dividend payment and ESOP.	T+3	Within 07 business days from SSC's notification of receipt of complete issuance report documents.
3	Disclosure of the Board of Directors' Resolution on finalizing the list of shareholders for dividend share issuance.	T+6	At least 10 days before the expected record date.
4	Announcement of finalizing the list of shareholders for dividend share issuance.	T+6	
5	Record date for entitlement to receive shares from the dividend share issuance.	T+17	
6	Start date for receiving payments from investors for ESOP share issuance.	T+18	
7	Report on the results of the dividend share issuance.	T+22	Within 15 days from the closing date of the dividend share issuance (record date).
8	Disclosure of changes in outstanding shares after completing the dividend share issuance.	T+22	
9	Deadline for ESOP share purchase payments.	T+25	

NO.	CONTENT	TIMELINE (Business days)	NOTES
10	SSC issues a written confirmation of receipt of the report on the results of the dividend share issuance.	T+25	
11	Report on the results of the ESOP share issuance.	T+32	Within 10 days from the completion of the offering (payment deadline).
12	Disclosure of changes in outstanding shares after completing the ESOP share issuance.	T+32	
13	SSC issues a written confirmation of receipt of the report on the results of the ESOP share issuance.	T+35	Within 03 business days from the receipt of complete issuance result documents.
14	Request for unblocking the escrow account related to the ESOP share issuance.	T+37	
15	Registration of additional securities with the Vietnam Securities Depository and Clearing Corporation – Ho Chi Minh City Branch (CNVSDC).	T+37	Within 30 days from the completion of the offering.
16	Registration for trading changes with the Hanoi Stock Exchange (UpCom).	T+37	No later than 30 days from the SSC's approval letter.
17	CNVSDC issues an adjusted Securities Registration Certificate.	T+42	Within 05 business days from the receipt of complete and valid documents.
18	Hanoi Stock Exchange (UpCom) issues a Decision on changes to the trading registration.	T+43	Within 05 business days from the receipt of complete and valid documents.
19	Registration of the first trading date for newly issued shares.	T+48	Within 5 business days from HNX's approval of trading registration changes.

RESOLUTION

On the implementation of the plan for share issuance to pay 2024 dividends

- Pursuant to Enterprises Law No. 59/2020/QH14 dated June 17, 2020;
- Pursuant to Securities Law No. 54/2019/QH14 dated November 26, 2019;
- Pursuant to Decree No. 155/2020/ND-CP dated December 31, 2020, of the Government detailing and guiding the implementation of certain provisions of the Securities Law;
- Pursuant to Circular No. 118/2020/TT-BTC dated December 31, 2020, of the Ministry of Finance guiding certain contents on securities offering, issuance, public tender offers, share buybacks, public company registration, and public company delisting;
- Pursuant to Resolution No. 01/NQ-AGP.DHDCD dated March 08, 2025, of the 2025 Annual General Meeting of Shareholders;
- Pursuant to Minutes No. 01/BB-AGP.DHDCD dated March 08, 2025, of the 2025 Annual General Meeting of Shareholders;
- Pursuant to Proposal No. 02/TT-AGP.DHDCD dated February 14, 2025, on Profit distribution and Dividend payment;
- Pursuant to Proposal No. 04/TT-AGP.DHDCD dated February 14, 2025, on Approval of the plan for issuing shares to pay dividends for the year 2024;
- Pursuant to Minutes No. *02* /BB-AGP.HDQT dated *March. 25. 2025* of the Board of Directors;
- Pursuant to Charter of Agimexpharm Pharmaceutical Joint Stock Company ("Company").

RESOLVED:

Article 1: Approval of the implementation of the plan for share issuance as dividend payment for 2024, which was approved by the 2025 Annual General Meeting of Shareholders on March 8, 2025, as follows:

1. **Securities name:** Shares of Agimexpharm Pharmaceutical Joint Stock Company
2. **Type of securities:** Common shares
3. **Par value per share:** VND 10,000/share
4. **Current charter capital:** VND 231,439,410,000
5. **Total number of issued shares:** 23,143,941 shares
Of which:
 - Total number of outstanding shares: 23,143,941 shares
 - Total number of treasury shares: 0 shares
6. **Estimated number of shares to be issued:** 2,314,394 shares
7. **Total value of issuance at par value:** VND 23,143,940,000
8. **Eligible subscriber:** Existing shareholders whose names appear on the shareholder list as of the record date. The record date for the shareholder list will be determined by the Board of Directors, as authorized by the General Meeting of Shareholders.
9. **Issuance ratio** (estimated number of shares to be issued/number of outstanding shares): 10%
10. **Subscription ratio:** 10:01. Shareholders holding 1 share will receive 1 right. Every 10 rights will be entitled to receive 1 new share.



- 11. Source of issuance funds:** Retained earnings after tax as of December 31, 2024, based on the audited financial statements for the year 2024 of Agimexpharm Pharmaceutical Joint Stock Company.
- 12. Issuance method:** The shares issued to existing shareholders will be distributed through the exercise of subscription rights.
- 13. Handling of fractional shares:** The number of additional shares issued to each shareholder will be rounded down to the nearest whole number. Any fractional shares (if any) will be canceled.

*For example: Shareholder A owns 128 shares on the record date. With an entitlement ratio of 10:01, Shareholder A will receive $(128/10 * 01) = 12.80$ new shares. Based on the rounding rule, Shareholder A will receive 12 new shares. The fractional 0.80 share will be canceled.*

The positive difference between the total expected issuance value of dividend shares (calculated at the par value of VND 10,000 per share) and the total actual value of distributed shares (calculated at the par value of VND 10,000 per share) will be allocated to the Company's Development Investment Fund.

- 14. Expected time of issuance:** After the State Securities Commission (SSC) acknowledges receipt of the complete issuance report from the Company, the issuance is expected to take place in the second to fourth quarter of 2025. The General Meeting of Shareholders authorizes the Board of Directors to determine the appropriate issuance time to ensure shareholders' interests and compliance with legal regulations.
- 15. Additional securities registration and additional trading registration:** The GMS approves and authorizes the BoDs to carry out the procedures for additional securities registration with the Viet Nam Securities Depository and Clearing Corporation – Ho Chi Minh City Branch and additional trading registration with the Hanoi Stock Exchange.
- 16. Approval of charter capital amendment:** Approve the amendment of the Company's Charter (regarding charter capital) and the adjustment of the Enterprise Registration Certificate with the Department of Planning and Investment of An Giang Province, following the written notification from the SSC confirming receipt of the issuance result report.

Article 2: The Board of Directors assigns the General Director to implement the share issuance plan for dividend payment, specifically:

- Carry out the procedures for submitting the application dossier for share issuance as dividend payment to the State Securities Commission (SSC) and provide explanations on related matters when required;
- Prepare and submit for approval by the Board of Directors all necessary documents for the registration of additional securities with the Vietnam Securities Depository and Clearing Corporation – Ho Chi Minh City Branch (CNVSDC) and the additional listing of securities on the Hanoi Stock Exchange after receiving approval from the SSC;
- Complete the information disclosure procedures in accordance with legal regulations.

Article 3: Members of the Board of Directors and the Executive Board of Agimexpharm Pharmaceutical Joint Stock Company are responsible for implementing this Resolution. This Resolution takes effect from the date of signing.

Recipients:

- As stated in Article 3;
- Archived: Secretary of the BoDs.

ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRWOMAN



PHẠM PHAM THI BICH THUY